AR069799A1 - Composicion farmaceutica - Google Patents
Composicion farmaceuticaInfo
- Publication number
- AR069799A1 AR069799A1 ARP080105520A ARP080105520A AR069799A1 AR 069799 A1 AR069799 A1 AR 069799A1 AR P080105520 A ARP080105520 A AR P080105520A AR P080105520 A ARP080105520 A AR P080105520A AR 069799 A1 AR069799 A1 AR 069799A1
- Authority
- AR
- Argentina
- Prior art keywords
- lubricant
- composition
- optionally
- quinazolin
- pyrrol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 10
- 239000000314 lubricant Substances 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000007884 disintegrant Substances 0.000 abstract 2
- 239000000945 filler Substances 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 abstract 1
- 102000003923 Protein Kinase C Human genes 0.000 abstract 1
- 108090000315 Protein Kinase C Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
Abstract
La solicitud se refiere a composiciones farmacéuticas solidas adecuadas para administracion oral, las cuales comprenden un derivado de indolil-maleimida, a un proceso para su produccion, y al uso de las composiciones farmacéuticas. Reivindicacion 1: Una composicion farmacéutica solida adecuada para administracion oral, la cual comprende la 3-(1.H,-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-iI]-pirrol-2,5-diona, o una sal farmacéuticamente aceptable de la misma, y cuando menos un lubricante, en donde la composicion comprende del 2 al 15 por ciento en peso de lubricante, y la composicion está en la forma de una tableta, siendo el peso total de la composicion el peso total del nucleo de la tableta. Reivindicacion 9: Una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 7, para utilizarse en la prevencion o el tratamiento de los trastornos o las enfermedades mediadas por los linfocitos-T y/o por la cinasa C de proteína, en un sujeto que necesite dicho tratamiento. Reivindicacion 11: Un proceso para la produccion de una tableta de acuerdo con cualquiera de las reivindicaciones 1 a 7, el cual comprende: (a) mezclar un relleno, un aglutinante, y opcionalmente un desintegrante, en una solucion acuosa, y granular la mezcla obtenida; (b) secar y moler los granulados obtenidos en (a), y mezclarlos con un lubricante; (c) opcionalmente mezclar la 3-(1.H.-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona, o una sal farmacéuticamente aceptable de la misma, con cuando menos un excipiente adicional seleccionado a partir de un relleno, un desintegrante, un derrapante, un aglutinante, y un lubricante; (d) mezclar ya sea directamente la 3-(1.H.-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona, o una sal farmacéuticamente aceptable de la misma, o bien la mezcla obtenida en el paso (c), con los granulados obtenidos en el paso (b), opcionalmente en la presencia de un lubricante; (e) formar las tabletas con la mezcla obtenida en el paso (b), (c), o (d), y (f) opcionalmente recubrir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07150347 | 2007-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069799A1 true AR069799A1 (es) | 2010-02-17 |
Family
ID=39495348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105520A AR069799A1 (es) | 2007-12-21 | 2008-12-18 | Composicion farmaceutica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100316713A1 (es) |
| EP (1) | EP2240164A2 (es) |
| JP (2) | JP5525453B2 (es) |
| KR (1) | KR20100103625A (es) |
| CN (1) | CN101883558A (es) |
| AR (1) | AR069799A1 (es) |
| AU (1) | AU2008340019B2 (es) |
| BR (1) | BRPI0820839A2 (es) |
| CA (1) | CA2709909A1 (es) |
| CL (1) | CL2008003823A1 (es) |
| CO (1) | CO6382170A2 (es) |
| EC (1) | ECSP10010360A (es) |
| IL (1) | IL205931A0 (es) |
| MA (1) | MA31950B1 (es) |
| MY (1) | MY158293A (es) |
| NZ (1) | NZ586313A (es) |
| PE (1) | PE20091522A1 (es) |
| RU (1) | RU2485951C2 (es) |
| TN (1) | TN2010000243A1 (es) |
| TW (1) | TWI449541B (es) |
| WO (1) | WO2009080762A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091522A1 (es) * | 2007-12-21 | 2009-10-29 | Novartis Ag | Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona |
| FR3069545B1 (fr) * | 2017-07-27 | 2020-10-16 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | Composition d'enrobage exempte de dioxyde de titane |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE22798A1 (es) * | 1995-11-20 | 1998-05-11 | Lilly Co Eli | Inhibidor de proteina quinasa c |
| AR039209A1 (es) * | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
| ES2572980T3 (es) * | 2005-06-02 | 2016-06-03 | Merck Sharp & Dohme Corp. | Combinación de inhibidores de la proteasa del VHC con un tensioactivo |
| NZ564789A (en) * | 2005-07-22 | 2010-07-30 | Myriad Genetics Inc | High drug load formulations and dosage forms |
| US7762932B2 (en) * | 2007-09-17 | 2010-07-27 | Fitness Anywhere, Inc. | Inelastic exercise device having a limited range |
| PE20091522A1 (es) * | 2007-12-21 | 2009-10-29 | Novartis Ag | Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona |
-
2008
- 2008-12-18 PE PE2008002124A patent/PE20091522A1/es not_active Application Discontinuation
- 2008-12-18 AR ARP080105520A patent/AR069799A1/es unknown
- 2008-12-19 AU AU2008340019A patent/AU2008340019B2/en not_active Ceased
- 2008-12-19 US US12/808,905 patent/US20100316713A1/en not_active Abandoned
- 2008-12-19 JP JP2010538767A patent/JP5525453B2/ja not_active Expired - Fee Related
- 2008-12-19 CN CN2008801190561A patent/CN101883558A/zh active Pending
- 2008-12-19 KR KR1020107016148A patent/KR20100103625A/ko not_active Ceased
- 2008-12-19 EP EP08865096A patent/EP2240164A2/en not_active Withdrawn
- 2008-12-19 CA CA2709909A patent/CA2709909A1/en not_active Abandoned
- 2008-12-19 CL CL2008003823A patent/CL2008003823A1/es unknown
- 2008-12-19 BR BRPI0820839-5A patent/BRPI0820839A2/pt not_active IP Right Cessation
- 2008-12-19 WO PCT/EP2008/068051 patent/WO2009080762A2/en not_active Ceased
- 2008-12-19 MY MYPI2010002374A patent/MY158293A/en unknown
- 2008-12-19 NZ NZ586313A patent/NZ586313A/xx not_active IP Right Cessation
- 2008-12-19 TW TW097149851A patent/TWI449541B/zh not_active IP Right Cessation
- 2008-12-19 RU RU2010129544/15A patent/RU2485951C2/ru not_active IP Right Cessation
-
2010
- 2010-05-24 IL IL205931A patent/IL205931A0/en unknown
- 2010-05-28 TN TN2010000243A patent/TN2010000243A1/fr unknown
- 2010-06-29 MA MA32969A patent/MA31950B1/fr unknown
- 2010-07-20 EC EC2010010360A patent/ECSP10010360A/es unknown
- 2010-07-21 CO CO10088697A patent/CO6382170A2/es not_active Application Discontinuation
-
2013
- 2013-11-15 JP JP2013236787A patent/JP2014040477A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0820839A2 (pt) | 2015-06-16 |
| TWI449541B (zh) | 2014-08-21 |
| RU2485951C2 (ru) | 2013-06-27 |
| IL205931A0 (en) | 2010-11-30 |
| AU2008340019A1 (en) | 2009-07-02 |
| JP2011506576A (ja) | 2011-03-03 |
| CN101883558A (zh) | 2010-11-10 |
| US20100316713A1 (en) | 2010-12-16 |
| TN2010000243A1 (en) | 2011-11-11 |
| MY158293A (en) | 2016-09-30 |
| AU2008340019B2 (en) | 2012-05-03 |
| WO2009080762A3 (en) | 2009-09-11 |
| TW200940106A (en) | 2009-10-01 |
| RU2010129544A (ru) | 2012-01-27 |
| JP2014040477A (ja) | 2014-03-06 |
| EP2240164A2 (en) | 2010-10-20 |
| JP5525453B2 (ja) | 2014-06-18 |
| PE20091522A1 (es) | 2009-10-29 |
| ECSP10010360A (es) | 2010-08-31 |
| CO6382170A2 (es) | 2012-02-15 |
| WO2009080762A2 (en) | 2009-07-02 |
| NZ586313A (en) | 2012-08-31 |
| MA31950B1 (fr) | 2010-12-01 |
| CL2008003823A1 (es) | 2010-01-22 |
| KR20100103625A (ko) | 2010-09-27 |
| CA2709909A1 (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Freret et al. | Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice | |
| CY1115652T1 (el) | Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες | |
| MA38391B1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| AR078846A1 (es) | Composicion para el tratamiento de la enfermedad de alzheimer | |
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| PE20141072A1 (es) | Composiciones farmaceuticas de accion doble basadas en el bloqueo de los receptores de angiotensina y la inhibicion de la endopeptidasa neutral | |
| EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| EA201490477A1 (ru) | Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина | |
| NO20076634L (no) | Erythropoietin reseptorpeptidformuleringer og anvendelser | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| EA201190020A1 (ru) | Производные изоиндола в качестве ингибиторов васе и их применение | |
| WO2008023258A8 (en) | Piperidine derivatives | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
| AR063983A1 (es) | Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada | |
| TNSN07337A1 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
| JP2013518914A5 (es) | ||
| ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
| AR099385A1 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
| CN105492010A (zh) | 用于治疗相移睡眠障碍的V1a拮抗剂 | |
| EA200970432A1 (ru) | 8-сульфонил-1,3,4,8-тетрагидро-2н-[1,4]оксазепино[6,7-e] индольные производные и их использование в качестве 5-нт6 рецепторных лигандов | |
| NO20092067L (no) | 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander | |
| AR069799A1 (es) | Composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |